Characteristics | Patients with OP, n = 24 | Patients without OP, n = 29 | p |
---|---|---|---|
Age, yrs | 63 (56–70) | 60 (48–69) | 0.6 |
Female, n (%) | 18 (75) | 25 (86) | 0.5 |
RA duration, mos | 85 (38–193) | 96 (33–187) | 0.9 |
MTX, n (%) | 19 (79) | 23 (82) | 1.0 |
MTX doses, mg/week | 8.0 (0.5–10.0) | 6.0 (4.0–8.0) | 0.6 |
PSL, n (%) | 10 (42) | 8 (29) | 0.4 |
Oral PSL doses, mg/day | 0 (0–3.8) | 0 (0–1.8) | 0.2 |
bDMARD, n (%) | 12 (50) | 15 (52) | 1.0 |
RF levels, IU/ml | 99 (41–273) | 48 (19–116) | 0.14 |
DAS28-ESR | 3.0 (2.1–4.0) | 2.5 (2.0–3.7) | 0.4 |
DAS28-ESR < 3.2, n (%) | 13 (54) | 19 (66) | 0.6 |
ILD, n (%) | 4 (17) | 3 (11) | 0.7 |
OP: organizing pneumonia; RA: rheumatoid arthritis; MTX: methotrexate; PSL: prednisolone; bDMARD: biologic disease-modifying antirheumatic drugs; RF: rheumatoid factor; DAS28: Disease Activity Score at 28 joints; ESR: erythrocyte sedimentation rate; ILD: interstitial lung disease.